Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.92%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B+0.02%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA+0.07%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%1816.HK+3.45%HD+0.06%3988.HK-1.13%BAC+0.05%GE0.00%0857.HK-0.49%ORCL-0.01%UNH+0.02%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.14%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%CADJPY0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CHFJPY0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%EURPLN0.00%NZDMXN0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+2.59%ETHUSD+77.41%USDTUSD+0.09%XRPUSD+64.83%SOLUSD+72.04%TRXUSDT+1.25%ZECUSDT+4.46%XMRUSDT+7.09%DOGEUSD+72.43%LINKUSD+1.03%XLMUSD+1.76%BCHUSDT+2.47%LTCUSD+64.72%UNIUSD+5.25%TONUSD+74.91%SUIUSD-0.68%HBARUSDT+0.39%TAOUSDT+2.40%AAVEUSD-0.71%ONDOUSDT-0.62%DOTUSDT-1.60%ICPUSDT-5.80%WLDUSDT-0.52%ARBUSDT-0.96%ATOMUSDT-3.84%INJUSDT-4.57%STXUSDT+2.91%PYTHUSDT+0.33%TIAUSDT-1.31%FETUSDT-3.07%SEIUSDT-1.94%JUPUSDT-4.27%GRTUSDT+0.60%OPUSDT+0.63%IOTAUSDT-1.77%POLUSDT-0.09%WIFUSDT-2.78%AXSUSDT+0.59%EOSUSDT+0.85%IMXUSDT-3.33%FARTCOINUSDT-0.20%GALAUSDT-2.18%DYDXUSDT-3.52%ORDIUSDT-0.27%NOTUSDT-1.52%RONINUSDT+0.62%AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.92%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B+0.02%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA+0.07%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%1816.HK+3.45%HD+0.06%3988.HK-1.13%BAC+0.05%GE0.00%0857.HK-0.49%ORCL-0.01%UNH+0.02%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.14%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%CADJPY0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CHFJPY0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%EURPLN0.00%NZDMXN0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+2.59%ETHUSD+77.41%USDTUSD+0.09%XRPUSD+64.83%SOLUSD+72.04%TRXUSDT+1.25%ZECUSDT+4.46%XMRUSDT+7.09%DOGEUSD+72.43%LINKUSD+1.03%XLMUSD+1.76%BCHUSDT+2.47%LTCUSD+64.72%UNIUSD+5.25%TONUSD+74.91%SUIUSD-0.68%HBARUSDT+0.39%TAOUSDT+2.40%AAVEUSD-0.71%ONDOUSDT-0.62%DOTUSDT-1.60%ICPUSDT-5.80%WLDUSDT-0.52%ARBUSDT-0.96%ATOMUSDT-3.84%INJUSDT-4.57%STXUSDT+2.91%PYTHUSDT+0.33%TIAUSDT-1.31%FETUSDT-3.07%SEIUSDT-1.94%JUPUSDT-4.27%GRTUSDT+0.60%OPUSDT+0.63%IOTAUSDT-1.77%POLUSDT-0.09%WIFUSDT-2.78%AXSUSDT+0.59%EOSUSDT+0.85%IMXUSDT-3.33%FARTCOINUSDT-0.20%GALAUSDT-2.18%DYDXUSDT-3.52%ORDIUSDT-0.27%NOTUSDT-1.52%RONINUSDT+0.62%

Thermo Fisher lifts medium‑term growth view

NEWS

November 19, 2026 at 16:06 UTC

4 min read
Modern lab instruments in a biomedical research lab illustrating Thermo Fisher growth outlook

Key Points

  • 01Thermo Fisher projects about 4% organic growth for 2026, with ~5% in H2
  • 02Management expects 2027 growth to strengthen within the 3%–6% organic range
  • 03The company is maintaining its target of 7% organic growth by 2028
  • 04Pharma and biotech, about 60% of revenue, are growing high single digits

Thermo Fisher outlines stronger 2027–2028 growth path

Thermo Fisher Scientific has presented a brighter medium-term outlook, projecting about 4% organic growth in 2026 with roughly 5% growth in the second half of the year. Management expects 2027 growth to strengthen while remaining within the company’s 3%–6% organic growth range, improving on 2026’s pace. Formal guidance for 2027 is scheduled for early February. The company is maintaining its objective of achieving 7% organic growth by 2028 and states that it does not see a cap on upside potential.

Chairman and CEO Marc Casper said the growth acceleration is expected as biotech spending recovers and research markets improve. He highlighted that end markets are not yet at peak recovery, suggesting additional room for growth through 2027 and into 2028. The outlook assumes that end markets will return to more normal long-term growth rates by 2028, supported by a stronger biotech environment, more stable academic spending, reshoring and artificial intelligence.

Pharma and biotech demand as main growth engine

Pharma and biotech customers remain Thermo Fisher’s primary growth driver, accounting for about 60% of company revenue. This end market grew at a high-single-digit rate in the most recent quarter, and Casper described the industry as recovering rather than operating at a peak. Large pharmaceutical companies are investing in their pipelines as they prepare for patent expirations later in the decade, while biotech funding has roughly doubled year over year in terms of new capital entering the market.

Management noted that biotech spending is still concentrated in later-stage development, but expects early research spending to increase as companies refill their pipelines. Thermo Fisher is already seeing more demand for basic lab supplies through its Fisher Scientific channel and reports “green shoots” in biosciences and genetic sciences, which are more exposed to early-stage biotech research. The company anticipates that these early research markets will improve during 2027.

Academic, government and China trends

Academic and government revenue was flat in the latest reported quarter, and Thermo Fisher expects a slight decline for the full year. Casper said he anticipates the academic market returning to low-single-digit growth over the next couple of years, with the U.S. academic market expected to return to growth in 2027. Management also indicated that academic and government spending is stabilizing after a period of uneven demand.

China, which represents about 7.5% of Thermo Fisher’s revenue, delivered low-double-digit growth in the third quarter. The performance was driven by demand from pharma and biotech customers and from semiconductor manufacturers using the company’s electron microscopes. While recent quarters have been strong, the company’s planning framework still assumes China will be a slight drag on average growth, though it is viewed as a potential source of upside.

Business segment performance and strategic drivers

In Life Sciences Solutions, bioproduction has been growing faster than its expected long-term rate of high-single-digit to low-double-digit growth, creating tougher comparisons in the near term. The company expects bioproduction growth to normalize toward those historical levels, while biosciences and genetic sciences are currently softer but show early signs of improvement. Analytical Instruments grew at a mid-single-digit rate, supported by electron microscopy, chromatography and mass spectrometry, with strong demand for a new Orbitrap mass spectrometer and proteomics work.

Pharma services have exceeded expectations, helped by clinical trial packaging, logistics, finished drug production and active pharmaceutical ingredient processing, as well as production timing. Clinical research is growing at a mid-single-digit rate, with new wins and authorizations exceeding revenue, and book-to-bill trends indicating potential for better growth by 2027. Management sees additional support from U.S. manufacturing reshoring and the use of AI in areas such as autonomous laboratories and clinical trials, as customers seek to improve research productivity and returns on R&D spending.

Key Takeaways

  • 01Thermo Fisher is signaling a transition from low to mid-range organic growth toward its targeted 7% by 2028, underpinned by an improving demand backdrop.
  • 02Pharma and biotech, reinforced by stronger funding and pipeline investment, are expected to continue leading growth while earlier-stage research gradually recovers.
  • 03Stabilizing academic budgets, solid China performance and contributions from bioproduction, analytical instruments and pharma services form multiple levers for the 2027–2028 outlook.

Thermo Fisher lifts medium‑term growth view | Trading Dashboard